features: Prostate Cancer
177Lu-PSMA-617 approved for use in patients with PSMA+ mCRPC
As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…
Top 5 picks from ASCO GU 2022
Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!
PHS290: a novel scoring algorithm provides a promising approach to screening for prostate cancer in diverse populations
A novel polygenic hazard score (PHS), PHS290, accurately predicts lifetime risks of developing metastatic or terminal prostate cancer across multiple…
Key updates from EAU 2021
VJOncology presents highlights from this year’sEuropean Association of Urology (EAU) Virtual Meeting 2021!
Top picks from ASCO 2021
VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!